This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liem, A. Articles by van Veldhuisen, D. J. Search for Related Content PubMed PubMed Citation Articles by Liem, A. Articles by van Veldhuisen, D. J.

Secondary prevention with folic acid: effects on clinical outcomes

Anho Liem, MD^*,*, Giny H. Reynierse-Buitenwerf^*, Aeilko H. Zwinderman, PhD, J. Wouter Jukema, MD, FACC and Dirk J. van Veldhuisen, MD, FACC

^* Department of Cardiology, Oosterschelde Ziekenhuizen, Goes, The Netherlands
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Leiden University Medical Center, Leiden, The Netherlands
University Hospital, Groningen, The Netherlands

View larger version (15K): [in a new window]   Figure 1 Cumulative event rate according to randomization to folic acid treatment (solid line) and control (dashed line). (A) Analysis for the entire group and (B) for patients with the highest quartile (Q-4) for baseline plasma homocysteine level ( 13.7 µmol/l). Probability value by log-rank statistic.

View larger version (15K): [in a new window]   Figure 2 Cumulative rate of first cardiovascular event for two markers. Kaplan-Meier cumulative event rates for top-risk quartile (dashed line) versus lower three risk quartiles (solid line) are shown for fibrinogen (A) and homocysteine (B). The Q-4 is top-risk quartile for fibrinogen ( 5 g/l) and homocysteine ( 13.7 µmol/l). Value by log-rank statistic.